These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 18426742)

  • 1. LDL species heterogeneity in the atherogenic dyslipidemia of polycystic ovary syndrome.
    Doi SA; Abbas JM; Parkinson L; Chakraborty J; Akanji AO
    Am J Clin Pathol; 2008 May; 129(5):802-10. PubMed ID: 18426742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype.
    Rizzo M; Berneis K; Hersberger M; Pepe I; Di Fede G; Rini GB; Spinas GA; Carmina E
    Hum Reprod; 2009 Sep; 24(9):2286-92. PubMed ID: 19454589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atherogenic changes in low-density lipoprotein particle profiles were not observed in non-obese women with polycystic ovary syndrome.
    Kim JJ; Chae SJ; Choi YM; Hwang KR; Song SH; Yoon SH; Kim SM; Ku SY; Kim SH; Kim JG; Moon SY
    Hum Reprod; 2013 May; 28(5):1354-60. PubMed ID: 23477907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome.
    Berneis K; Rizzo M; Hersberger M; Rini GB; Di Fede G; Pepe I; Spinas GA; Carmina E
    Int J Clin Pract; 2009 Jan; 63(1):56-62. PubMed ID: 19125993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How should we manage atherogenic dyslipidemia in women with polycystic ovary syndrome?
    Rizzo M; Berneis K; Carmina E; Rini GB
    Am J Obstet Gynecol; 2008 Jan; 198(1):28.e1-5. PubMed ID: 18166299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of endothelial dysfunction, lipid metabolism in women with polycystic ovary syndrome: relationship of paraoxonase 1 activity, malondialdehyde levels, low-density lipoprotein subfractions, and endothelial dysfunction.
    Bayram F; Kocer D; Ozsan M; Muhtaroglu S
    Gynecol Endocrinol; 2012 Jul; 28(7):497-501. PubMed ID: 22703625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of obesity on atherogenic dyslipidemia in women with polycystic ovary syndrome.
    Hernández-Mijares A; Bañuls C; Gómez-Balaguer M; Bergoglio M; Víctor VM; Rocha M
    Eur J Clin Invest; 2013 Jun; 43(6):549-56. PubMed ID: 23528141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathophysiology and types of dyslipidemia in PCOS.
    Diamanti-Kandarakis E; Papavassiliou AG; Kandarakis SA; Chrousos GP
    Trends Endocrinol Metab; 2007 Sep; 18(7):280-5. PubMed ID: 17692530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Smaller LDL particle size in women with polycystic ovary syndrome compared to controls.
    Dejager S; Pichard C; Giral P; Bruckert E; Federspield MC; Beucler I; Turpin G
    Clin Endocrinol (Oxf); 2001 Apr; 54(4):455-62. PubMed ID: 11318780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome.
    Berneis K; Rizzo M; Lazzarini V; Fruzzetti F; Carmina E
    J Clin Endocrinol Metab; 2007 Jan; 92(1):186-9. PubMed ID: 17062762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is the best predictor of the atherogenic LDL subclass phenotype 'pattern B' in patients with type 2 diabetes mellitus?
    King RI; Florkowski CM; Yeo J; Walmsley TA; Shand BI; Scott RS; George PM
    Ann Clin Biochem; 2011 Mar; 48(Pt 2):166-9. PubMed ID: 21278248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia.
    Kostapanos MS; Milionis HJ; Lagos KG; Rizos CB; Tselepis AD; Elisaf MS
    Eur J Pharmacol; 2008 Aug; 590(1-3):327-32. PubMed ID: 18585701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adolescent girls with polycystic ovary syndrome showing different phenotypes have a different metabolic profile associated with increasing androgen levels.
    Fruzzetti F; Perini D; Lazzarini V; Parrini D; Genazzani AR
    Fertil Steril; 2009 Aug; 92(2):626-34. PubMed ID: 18706545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atherogenic lipoprotein phenotype and LDL size and subclasses in drug-naïve patients with early rheumatoid arthritis.
    Rizzo M; Spinas GA; Cesur M; Ozbalkan Z; Rini GB; Berneis K
    Atherosclerosis; 2009 Dec; 207(2):502-6. PubMed ID: 19643412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The predictive role of atherogenic dyslipidemia in subjects with non-coronary atherosclerosis.
    Berneis K; Rizzo M; Spinas GA; Di Lorenzo G; Di Fede G; Pepe I; Pernice V; Rini GB
    Clin Chim Acta; 2009 Aug; 406(1-2):36-40. PubMed ID: 19433079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiometabolic abnormalities in the polycystic ovary syndrome: pharmacotherapeutic insights.
    Westerveld HE; Hoogendoorn M; de Jong AW; Goverde AJ; Fauser BC; Dallinga-Thie GM
    Pharmacol Ther; 2008 Sep; 119(3):223-41. PubMed ID: 18602948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic syndrome in women with polycystic ovary syndrome.
    Essah PA; Nestler JE
    Fertil Steril; 2006 Jul; 86 Suppl 1():S18-9. PubMed ID: 16798277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dyslipidemia and oxidative stress in PCOS.
    Macut D; Bjekić-Macut J; Savić-Radojević A
    Front Horm Res; 2013; 40():51-63. PubMed ID: 24002405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there a role for soy isoflavones in the therapeutic approach to polycystic ovary syndrome? Results from a pilot study.
    Romualdi D; Costantini B; Campagna G; Lanzone A; Guido M
    Fertil Steril; 2008 Nov; 90(5):1826-33. PubMed ID: 18166189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dyslipidemia in PCOS.
    Wild RA
    Steroids; 2012 Mar; 77(4):295-9. PubMed ID: 22197663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.